(19)
(11) EP 3 159 405 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
07.11.2018 Bulletin 2018/45

(45) Mention of the grant of the patent:
12.09.2018 Bulletin 2018/37

(21) Application number: 16196233.7

(22) Date of filing: 05.01.2011
(51) International Patent Classification (IPC): 
C12N 15/00(2006.01)

(54)

METHODS FOR USE OF A SPECIFIC ANTI-ANGIOGENIC ADENOVIRAL AGENT

VERFAHREN ZUR VERWENDUNG EINES SPEZIFISCHEN ADENOVIRENMITTELS GEGEN ANGIOGENESE

PROCÉDÉS POUR L'UTILISATION D'UN AGENT ADÉNOVIRAL ANTIANGIOGENÈSE SPÉCIFIQUE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 05.01.2010 US 282228 P
07.01.2010 US 282247 P

(43) Date of publication of application:
26.04.2017 Bulletin 2017/17

(62) Application number of the earlier application in accordance with Art. 76 EPC:
11731733.9 / 2521776

(73) Proprietor: Vascular Biogenics Ltd.
Modiin 7178106 (IL)

(72) Inventors:
  • COHEN, Yael
    55602 Kiryat-Ono (IL)
  • SHER, Naamit
    76248 Rechovot (IL)
  • FEIGE, Erez
    50295 Hemed (IL)
  • BANGIO, Livnat
    49776 Petah-Tikva (IL)
  • BREITBART, Eyal
    73127 Hashmonaim (IL)

(74) Representative: Vossius & Partner Patentanwälte Rechtsanwälte mbB 
Siebertstrasse 3
81675 München
81675 München (DE)


(56) References cited: : 
WO-A1-00/61150
US-A1- 2004 197 860
 WO-A2-2007/096882
US-A1- 2007 286 845
   
  • GREENBERGER S ET AL: "Transcription-control led gene therapy against tumor angiogenesis", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 113, no. 7, 1 April 2004 (2004-04-01) , pages 1017-1024, XP002349281, ISSN: 0021-9738, DOI: 10.1172/JCI200420007
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).